GENSCRIPT BIO (01548) extended its gains, rising over 5% and trading 3.95% higher at HK$19.49 as of the latest update, with turnover reaching HK$287 million.
The company plans to hold a board meeting on August 15 to approve its interim results. According to a previous announcement, in the second quarter, Legend Biotech's CARVYKTI sales reached US$657 million, a year-on-year increase of 49.4% and a sequential rise of 10%. First-half sales totaled US$1.254 billion, up 55.1% from the same period last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments